GlobeNewsWire
17 Jul 2026, 16:53 UTC · 48m ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ADMA Biologics is facing a class action lawsuit alleging the use of 'channel stuffing' to artificially inflate revenue growth. — Allegations of fraudulent accounting and revenue manipulation typically lead to significant valuation haircuts and loss of investor trust.
-0.80A Culper Research report alleged ADMA's 2025 real growth was -3% despite reporting 20%. — A massive discrepancy between reported and actual growth suggests a fundamental failure in business performance and reporting integrity.
-0.70The lawsuit claims ADMA engaged in undisclosed related party transactions and lacked adequate internal controls. — Poor internal controls and undisclosed related party deals are red flags for governance risks and potential further regulatory penalties.
-0.60Continue reading
6 related stories
Search tags
The deadline for investors to file a lead plaintiff motion in the securities fraud case is August 10, 2026. — While procedural, the formalization of a class action increases the likelihood of a costly legal settlement.
-0.20Which stocks this story touches
The company is facing a securities fraud class action lawsuit following allegations of channel stuffing and misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
